It was the view of the Committee that it would be more viable for South Africa to produce some of the anti-viral (ARV) drugs that are imported from other part of the world, given the volumes imported and the costs thereof. The National Department of Health pointed out that South Africa accounted for 25 per cent of the global ARV market. It added that, in order to ensure security of supplies, the country should produce locally. Engagements in this regard were underway.